Associations between gut microbiota and sarcopenia or its defining parameters in older adults: A systematic review.
Gut microbiota
Muscle mass
Muscle strength
Older adults
Physical performance
Sarcopenia
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
revised:
09
07
2024
received:
04
03
2024
accepted:
18
07
2024
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
28
8
2024
Statut:
aheadofprint
Résumé
Altered gut microbiota (GM) potentially contribute to development or worsening of sarcopenia through a gut-muscle axis. This systematic review aims to compare GM between persons with sarcopenia or low sarcopenia-defining parameters (muscle mass, strength, and physical performance) to those with preserved muscle status, as well as to clarify possible associations between sarcopenia (-defining parameters) and relative abundance (RA) of GM-taxa or GM-(α- or β) diversity indices, in order to clarify whether there is robust evidence of the existence of a GM signature for sarcopenia. This systematic review was conducted according to the PRISMA-reporting guideline and pre-registered on PROSPERO (CRD42021259597). PubMed, Web of Science, Embase, ClinicalTrials.gov, and Cochrane library were searched until 20 July 2023. Included studies reported on GM and sarcopenia or its defining parameters. Observational studies were included with populations of mean age ≥50 years. Thirty-two studies totalling 10 781 persons (58.56% ♀) were included. Thirteen studies defined sarcopenia as a construct. Nineteen studies reported at least one sarcopenia-defining parameter (muscle mass, strength or physical performance). Studies found different GM-taxa at multiple levels to be significantly associated with sarcopenia (n = 4/6), muscle mass (n = 13/14), strength (n = 7/9), and physical performance (n = 3/3); however, directions of associations were heterogeneous and also conflicting for specific GM-taxa. Regarding β-diversity, studies found GM of persons with sarcopenia, low muscle mass, or low strength to cluster differently compared with persons with preserved muscle status. α-diversity was low in persons with sarcopenia or low muscle mass as compared with those with preserved muscle status, indicating low richness and diversity. In line with this, α-diversity was significantly and positively associated with muscle mass (n = 3/4) and muscle strength (n = 2/3). All reported results were significant (P < 0.05). Persons with sarcopenia and low muscle parameters have less rich and diverse GM and can be separated from persons with preserved muscle mass and function based on GM-composition. Sarcopenia and low muscle parameters are also associated with different GM-taxa at multiple levels, but results were heterogeneous and no causal conclusions could be made due to the cross-sectional design of the studies. This emphasizes the need for uniformly designed cross-sectional and longitudinal trials with appropriate GM confounder control in large samples of persons with sarcopenia and clearly defined core outcome sets in order to further explore changes in GM-taxa and to determine a sarcopenia-specific GM-signature.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.
Références
Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz‐Jentoft AJ, Dent E, et al. Sarcopenia: a time for action. An SCWD position paper. J Cachexia Sarcopenia Muscle 2019;10:956–961.
Cruz‐Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European Consensus on Definition and Diagnosis. Age Ageing 2019;48:16–31.
Cruz‐Jentoft AJ, Sayer AA. Sarcopenia. The Lancet 2019;393:2636–2646.
Yuan S, Larsson SC. Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism 2023;155533.
Norman K, Otten L. Financial impact of sarcopenia or low muscle mass ‐ a short review. Clin Nutr 2019;38:1489–1495.
Petermann‐Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta‐analysis. J Cachexia Sarcopenia Muscle 2022;13:86–99.
Ghosh TS, Shanahan F, O'Toole PW. Toward an improved definition of a healthy microbiome for healthy aging. Nat Aging 2022;2:1054–1069.
Wilmanski T, Diener C, Rappaport N, Patwardhan S, Wiedrick J, Lapidus J, et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat Metab 2021;3:274–286.
Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease. Front Cell Infect Microbiol 2021;11:625913.
Ghosh TS, Das M, Jeffery IB, O'Toole PW. Adjusting for age improves identification of gut microbiome alterations in multiple diseases. Elife 2020;9.
Lahiri S, Kim H, Garcia‐Perez I, Reza MM, Martin KA, Kundu P, et al. The gut microbiota influences skeletal muscle mass and function in mice. Science Translational Medicine 2019;11:eaan5662.
Han DS, Wu WK, Liu PY, Yang YT, Hsu HC, Kuo CH, et al. Differences in the gut microbiome and reduced fecal butyrate in elders with low skeletal muscle mass. Clin Nutr 2022;41:1491–1500.
Kang L, Li P, Wang D, Wang T, Hao D, Qu X. Alterations in intestinal microbiota diversity, composition, and function in patients with sarcopenia. Scientific Reports 2021 11:1 2021;11:1–14.
Liu C, Cheung WH, Li J, Chow SK, Yu J, Wong SH, et al. Understanding the gut microbiota and sarcopenia: a systematic review. J Cachexia Sarcopenia Muscle 2021;12:1393–1407.
Vieira‐Silva S, Sabino J, Valles‐Colomer M, Falony G, Kathagen G, Caenepeel C, et al. Quantitative microbiome profiling disentangles inflammation‐ and bile duct obstruction‐associated microbiota alterations across PSC/IBD diagnoses. Nat Microbiol 2019;4:1826–1831.
Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D. Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2019;25:67–73.
Nikolova VL, Smith MRB, Hall LJ, Cleare AJ, Stone JM, Young AH. Perturbations in gut microbiota composition in psychiatric disorders: a review and meta‐analysis. JAMA Psychiatry 2021;78:1343–1354.
Nikkhah A, Ejtahed HS, Ettehad Marvasti F, Taghavi M, Pakmehr A, Hajipour F, et al. The critical role of gut microbiota dysbiosis in skeletal muscle wasting: a systematic review. J Appl Microbiol 2023;134.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLOS Medicine 2009;6:e1000097‐e.
Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De‐duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc 2016;104:240–243.
Proctor DN, Balagopal P, Nair KS. Age‐related sarcopenia in humans is associated with reduced synthetic rates of specific muscle proteins. J Nutr 1998;128:351S–355S.
Faulkner JA, Larkin LM, Claflin DR, Brooks SV. Age‐related changes in the structure and function of skeletal muscles. Clin Exp Pharmacol Physiol 2007;34:1091–1096.
Akoglu H. User's guide to correlation coefficients. Turk J Emerg Med 2018;18:91–93.
Thukral A. A review on measurement of alpha diversity in biology. Agric Res J 2017;54:1.
Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207–214.
Aoyagi Y, Amamoto R, Park S, Honda Y, Shimamoto K, Kushiro A, et al. Independent and interactive effects of habitually ingesting fermented milk products containing Lactobacillus casei strain Shirota and of engaging in moderate habitual daily physical activity on the intestinal health of older people. Front Microbiol 2019;10:1477.
Barger K, Langsetmo L, Orwoll ES, Lustgarten MS. Investigation of the diet‐gut‐muscle axis in the osteoporotic fractures in men study. J Nutr Health Aging 2020;24:445–452.
Bjørkhaug ST, Aanes H, Neupane SP, Bramness JG, Malvik S, Henriksen C, et al. Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption. Gut Microbes 2019;10:663–675.
Castro‐Mejía JL, Khakimov B, Krych Ł, Bülow J, Bechshøft RL, Højfeldt G, et al. Physical fitness in community‐dwelling older adults is linked to dietary intake, gut microbiota, and metabolomic signatures. Aging Cell 2020;19.
Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012 488:7410. 2012;488:178–184.
Houttu V, Boulund U, Nicolaou M, Holleboom AG, Grefhorst A, Galenkamp H, et al. Physical activity and dietary composition relate to differences in gut microbial patterns in a multi‐ethnic cohort‐the HELIUS study. Metabolites 2021;11.
Hu J, Zhong X, Liu Y, Yan J, Zhou D, Qin D, et al. Correlation between intestinal flora disruption and protein–energy wasting in patients with end‐stage renal disease. BMC Nephrol 2022;23.
Hung W‐C, Hung W‐W, Tsai H‐J, Chang C‐C, Chiu Y‐W, Hwang S‐J, et al. The association of targeted gut microbiota with body composition in type 2 diabetes mellitus. Int J Med Sci 2021;18:511–519.
Lim MY, Hong S, Kim J‐H, Nam Y‐D. Association between gut microbiome and frailty in the older adult population in Korea. J Gerontol A Biol Sci Med Sci 2021;76:1362–1368.
Margiotta E, Caldiroli L, Callegari ML, Miragoli F, Zanoni F, Armelloni S, et al. Association of sarcopenia and gut microbiota composition in older patients with advanced chronic kidney disease, investigation of the interactions with uremic toxins, inflammation and oxidative stress. Toxins 2021;13:472.
Margiotta E, Miragoli F, Callegari ML, Vettoretti S, Caldiroli L, Meneghini M, et al. Gut microbiota composition and frailty in elderly patients with chronic kidney disease. PLoS ONE 2020;15:e0228530.
Palmas V, Pisanu S, Madau V, Casula E, Deledda A, Cusano R, et al. Gut microbiota markers associated with obesity and overweight in Italian adults. Sci Rep 2021;11.
Picca A, Ponziani FR, Calvani R, Marini F, Biancolillo A, Coelho‐Júnior HJ, et al. Gut microbial, inflammatory and metabolic signatures in older people with physical frailty and sarcopenia: results from the BIOSPHERE study. Nutrients 2020, 2019;12:65.
Ticinesi A, Mancabelli L, Tagliaferri S, Nouvenne A, Milani C, del Rio D, et al. The gut‐muscle axis in older subjects with low muscle mass and performance: a proof of concept study exploring fecal microbiota composition and function with shotgun metagenomics sequencing. Int J Mol Sci 2020;21:8946.
Xu Y, Wang Y, Li H, Dai Y, Chen D, Wang M, et al. Altered fecal microbiota composition in older adults with frailty. Front Cell Infect Microbiol 2021;11:696186.
Yamamoto K, Ishizu Y, Honda T, Ito T, Imai N, Nakamura M, et al. Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease. Sci Rep 2022;12:3674.
Yan X, Xie R, Ding L, Cheng X, Xu J, Lin L, et al. Relationships between sarcopenia, nutrient intake, and gut microbiota in Chinese community‐dwelling older women. Arch Gerontol Geriatr 2023;113:105063.
Peng J, Gong H, Lyu X, Liu Y, Li S, Tan S, et al. Characteristics of the fecal microbiome and metabolome in older patients with heart failure and sarcopenia. Front Cell Infect Microbiol 2023;13:1127041.
Davis JA, Collier F, Mohebbi M, Pasco JA, Shivappa N, Hébert JR, et al. The associations of butyrate‐producing bacteria of the gut microbiome with diet quality and muscle health. Gut Microbiome 2021;2:e2.
Lee YA, Song SW, Jung SY, Bae J, Hwang N, Kim HN. Sarcopenia in community‐dwelling older adults is associated with the diversity and composition of the gut microbiota. Exp Gerontol 2022;167:111927.
Ponziani FR, Picca A, Marzetti E, Calvani R, Conta G, del Chierico F, et al. Characterization of the gut‐liver‐muscle axis in cirrhotic patients with sarcopenia. Liver Int 2021;41:1320–1334.
Dillon SM. A unique gut microbiome‐physical function axis exists in older people with HIV: an exploratory study. AIDS Res Hum Retroviruses 2021;37.
Wang Z, Xu X, Deji Y, Gao S, Wu C, Song Q, et al. Bifidobacterium as a potential biomarker of sarcopenia in elderly women. Nutrients 2023;15.
Wu Y, Xia YT, Huang SM, Liu SY, Yang J, Yang YM, et al. The composition of the gut microbiome in patients with sarcopenia. Turk Biyokim Derg.
Akashi K, Yokoyama Y, Mizuno T, Abe T, Fukaya M, Asahara T, et al. Association between preoperative muscle mass and intraoperative bacterial translocation in patients undergoing hepatectomy, pancreatoduodenectomy, and esophagectomy. Ann Surg Oncol 2019;26:4805–4813.
Šoltys KLL, Hric I, Baranovičová E, Penesová A, Mikula I, Bohmer M, et al. Strenuous physical training, physical fitness, body composition and bacteroides to prevotella ratio in the gut of elderly athletes. Front Physiol 2021;12:670989.
Tavella T, Rampelli S, Guidarelli G, Bazzocchi A, Gasperini C, Pujos‐Guillot E, et al. Elevated gut microbiome abundance of Christensenellaceae, Porphyromonadaceae and Rikenellaceae is associated with reduced visceral adipose tissue and healthier metabolic profile in Italian elderly. Gut Microbes. 2021;13:1880221.
Wang Y, Zhang Y, Lane NE, Wu J, Yang T, Li J, et al. Population‐based metagenomics analysis reveals altered gut microbiome in sarcopenia: data from the Xiangya Sarcopenia Study. J Cachexia Sarcopenia Muscle 2022;13:2340–2351.
Lee P‐C, Lee K‐C, Yang T‐C, Lu H‐S, Cheng T‐Y, Chen Y‐J, et al. Sarcopenia‐related gut microbial changes are associated with the risk of complications in people with cirrhosis. JHEP Rep 2023;5:100619.
Grahnemo L, Nethander M, Coward E, Gabrielsen ME, Sree S, Billod J‐M, et al. Identification of three bacterial species associated with increased appendicular lean mass: the HUNT study. Nat Commun 2023;14.
Farup PG, Maseng MG. Are faecal microbiota analyses on species‐level suitable clinical biomarkers? A pilot study in subjects with morbid obesity. Microorganisms 2021;9:664.
Fan Y, Støving RK, Berreira Ibraim S, Hyötyläinen T, Thirion F, Arora T, et al. The gut microbiota contributes to the pathogenesis of anorexia nervosa in humans and mice. Nat Microbiol 2023;8:787–802.
Machiels K, Joossens M, Sabino J, de Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate‐producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014;63:1275–1283.
Caenepeel C, Falony G, Machiels K, Verstockt B, Goncalves PJ, Ferrante M, et al. Dysbiosis and associated stool features improve prediction of response to biological therapy in inflammatory bowel disease. Gastroenterology 2023.
Vieira‐Silva S, Falony G, Belda E, Nielsen T, Aron‐Wisnewsky J, Chakaroun R, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 2020;581:310–315.
Siddharth J, Chakrabarti A, Pannérec A, Karaz S, Morin‐Rivron D, Masoodi M, et al. Aging and sarcopenia associate with specific interactions between gut microbes, serum biomarkers and host physiology in rats. Aging 2017;9:1698–1720.
Bindels LB, Beck R, Schakman O, Martin JC, de Backer F, Sohet FM, et al. Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS ONE 2012;7:e37971.
Vandeputte D, de Commer L, Tito RY, Kathagen G, Sabino J, Vermeire S, et al. Temporal variability in quantitative human gut microbiome profiles and implications for clinical research. Nat Commun 2021;12:6740.
Cawthon PM, Visser M, Arai H, Avila‐Funes JA, Barazzoni R, Bhasin S, et al. Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee. Eur Geriatr Med 2022;13:1239–1244.
Beaudart C, McCloskey E, Bruyere O, Cesari M, Rolland Y, Rizzoli R, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr 2016;16:170.
Beeri MS, Leugrans SE, Delbono O, Bennett DA, Buchman AS. Sarcopenia is associated with incident Alzheimer's dementia, mild cognitive impairment, and cognitive decline. J Am Geriatr Soc 2021;69:1826–1835.
Kirk B, Cawthon PM, Arai H, Avila‐Funes JA, Barazzoni R, Bhasin S, et al. The Conceptual definition of sarcopenia: delphi consensus from the global leadership initiative in sarcopenia (GLIS). Age Ageing. 2024;53(3).
Falony G, Joossens M, Vieira‐Silva S, Wang J, Darzi Y, Faust K, et al. Population‐level analysis of gut microbiome variation. Science 2016;352:560–564.
Li J, Chen D, Yu B, He J, Huang Z, Zheng P, et al. Batch and sampling time exert a larger influence on the fungal community than gastrointestinal location in model animals: a meaningful case study. Front Nutr 2022;9:1021215.
Randall DW, Kieswich J, Swann J, McCafferty K, Thiemermann C, Curtis M, et al. Batch effect exerts a bigger influence on the rat urinary metabolome and gut microbiota than uraemia: a cautionary tale. Microbiome 2019;7:127.
Nandhra GK, Mark EB, di Tanna GL, Haase AM, Poulsen J, Christodoulides S, et al. Normative values for region‐specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3D‐Transit electromagnet tracking system: influence of age, gender, and body mass index. Neurogastroenterol Motil 2020;32:e13734.
Jackson MA, Verdi S, Maxan ME, Shin CM, Zierer J, Bowyer RCE, et al. Gut microbiota associations with common diseases and prescription medications in a population‐based cohort. Nat Commun 2018;9:2655.
Tanaka T, Akishita M, Kojima T, Son BK, Iijima K. Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community‐dwelling Japanese older adults: a 9‐year Kashiwa cohort study. BMC Geriatr 2023;23:390.
Rashidah NH, Lim SM, Neoh CF, Majeed ABA, Tan MP, Khor HM, et al. Differential gut microbiota and intestinal permeability between frail and healthy older adults: a systematic review. Ageing Res Rev 2022;82:101744.
Wu WK, Chen CC, Panyod S, Chen RA, Wu MS, Sheen LY, et al. Optimization of fecal sample processing for microbiome study ‐ the journey from bathroom to bench. J Formos Med Assoc 2019;118:545–555.
Gargon E. The COMET (Core Outcome Measures in Effectiveness Trials) initiative. Maturitas 2016;91:91–92.
Reginster JY, Beaudart C, Al‐Daghri N, Avouac B, Bauer J, Bere N, et al. Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clin Exp Res 2021;33:3–17.